Kinnate Biopharma Inc
Change company Symbol lookup
Select an option...
KNTE Kinnate Biopharma Inc
JPM-K JPMorgan Chase & Co
KLAC KLA Corp
CNVY Convey Health Solutions Holdings Inc
EBAY eBay Inc
PRLX Parallax Health Sciences Inc
AXS AXIS Capital Holdings Ltd
SPNS Sapiens International Corporation NV
SPCE Virgin Galactic Holdings Inc
BBLG Bone Biologics Corp
Go

Health Care : Biotechnology |
Company profile

Kinnate Biopharma Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Its products candidate include KIN-2787, KIN-3248 and KIN004. The KIN-2787 is a small molecule kinase inhibitor targeting specific classes of BRAF kinase alterations that characterize subsets of lung cancer, melanoma and other solid tumors. The Company has initiated a Phase I clinical trial for KIN-2787 (KN-8701). KIN-3248 is a small-molecule kinase inhibitor targeting cancer-associated alterations in FGFR2 and FGFR3 genes. KIN-3248 address the initial alteration and clinically-observed and predicted mutations in FGFR2 fusion gene-positive intrahepatic cholangiocarcinoma and FGFR3-altered ulcerative colitis. It is also developing a CDK12 inhibitor candidate to target the treatment of ovarian carcinoma, metastatic castration-resistant prostate cancer and triple-negative breast cancer.

Closing Price
$14.81
Day's Change
0.01 (0.07%)
Bid
--
Ask
--
B/A Size
--
Day's High
15.16
Day's Low
14.40
Volume
(Heavy Day)
Volume:
170,150

10-day average volume:
94,439
170,150

Company Profile

Kinnate Biopharma Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Its products candidate include KIN-2787, KIN-3248 and KIN004. The KIN-2787 is a small molecule kinase inhibitor targeting specific classes of BRAF kinase alterations that characterize subsets of lung cancer, melanoma and other solid tumors. The Company has initiated a Phase I clinical trial for KIN-2787 (KN-8701). KIN-3248 is a small-molecule kinase inhibitor targeting cancer-associated alterations in FGFR2 and FGFR3 genes. KIN-3248 address the initial alteration and clinically-observed and predicted mutations in FGFR2 fusion gene-positive intrahepatic cholangiocarcinoma and FGFR3-altered ulcerative colitis. It is also developing a CDK12 inhibitor candidate to target the treatment of ovarian carcinoma, metastatic castration-resistant prostate cancer and triple-negative breast cancer.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
1.96x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

July 2022
Current Month
3.2M
Previous Month
3.4M
Percent of Float
9.67%
Days to Cover
29.2655 Days

Share Information

KNTE is in a share class of common stock
Float
43.9M
Shares Outstanding
44.0M
Institutions Holding Shares
122
94.09%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Dean Jonathan Mitchell
  • Nima FarzanPres.
  • Neha KrishnamohanCFO
  • Mark A. MeltzCOO
  • Richard WilliamsOther

Address

  • 11975 El Camino Real, Ste 101, Suite 101
  • San Diego, CA 92130
  • Phone: (858) 299-4699
  • Fax: (302) 655-5049
  • https://www.kinnate.com/

Insider Trading

During the most recent quarter, 431K shares were bought in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.